Short answer
CorMedix Inc. (CRMD) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (down 47.7% year over year) with net income of −$15M.
Q3 2026 key financials · XBRL
- Revenue
- $55M
- −47.7% YoY · −46.5% QoQ
- Net income
- −$15M
- −113.6% YoY · −156.6% QoQ
- Operating margin
- -12.1%
- Gross margin
- 55.0%
- EPS (diluted)
- −$0.15
- −110.8% YoY · −151.7% QoQ
Source: XBRL data from the CorMedix Inc. (CRMD) Q3 2026 10-Q on SEC EDGAR. USD.
CorMedix Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $54.5M, down 48% YoY from $104.3M, driven by lower DefenCath net pricing
- Gross margin 55.0% vs 89.3% YoY, with net income $14.7M loss vs $108.6M income
- DefenCath worst performer, product sales $17.2M vs $88.8M; Melinta Portfolio sales $31.4M vs $12.8M
- Cash and investments $355.2M vs $148.5M at December 31, 2025; operating cash flow $218.3M year to date
- CMS reimbursement headwind: $8.32 add-on effective January 2027, expected 2027 average at least twice $2.37 current rate
Risk Factors
- Acquisition risk: Heron transaction may fail closing conditions or stockholder vote, pressuring share price and results
- Regulatory risk: CMS post-TDAPA adjustment reduced DefenCath net pricing in 2H 2026
- Reimbursement risk: Quarterly CMS calculations begin in 2027, increasing DefenCath revenue volatility
- Financial risk: Proposed $150 million senior secured term loan would increase interest costs and repayment obligations
- Dilution risk: Heron would receive 14,583,333 shares, representing approximately 18.3% pro forma ownership
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CorMedix Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.